Skip to content
Pharmaceuticals
-
GSK’s Blujepa secures FDA approval for first new oral UTI antibiotic class in nearly 30 years
Blujepa is specifically designed to combat uncomplicated urinary tract infections (UTIs) caused by common bacteria, including Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.
-
-
-
-
-
-
-
-
-
